Lower Drug Costs for Families Act
- Bill Number
- S. 1186
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-27: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-06-03T11:03:23Z
AI-Generated Summary
Purpose
The "Lower Drug Costs for Families Act" (S. 1186) aims to reduce prescription drug prices by expanding the application of inflation rebates—payments drug manufacturers make when prices rise faster than inflation—to drugs sold in the commercial market (non-Medicare insurance plans). It also shifts the reference year for calculating these rebates from 2021 back to 2016, potentially increasing rebate amounts to better align with historical price trends.
Key Provisions
- Part B Drugs (Medicare Outpatient Coverage):
- Extends inflation rebates to all "billing units" (standardized units used for Medicare billing) of covered drugs, including those sold in the commercial market, by adjusting how total units are calculated and excluding only Medicaid units.
- Changes the base period for rebate calculations from July 1, 2021 (or January 2021) to July 1, 2016 (or January 2016), using data from two quarters prior to the rebate period.
- Effective for calendar quarters starting January 1, 2026.
- Part D Drugs (Medicare Prescription Drug Plans):
- Applies rebates to units used in average manufacturer price (AMP) calculations, excluding Medicaid units, Medicare Part B rebate units, and (starting 2026) units discounted under the 340B drug pricing program (a federal program providing discounted drugs to certain safety-net providers).
- Shifts the base period from October 1, 2021 (or January 2021) to October 1, 2016 (or January 2016).
- Relies on manufacturer reports under Section 1927 of the Social Security Act for implementation.
- Effective for applicable periods starting October 1, 2025.
- General Implementation:
- The Centers for Medicare & Medicaid Services (CMS) will use existing manufacturer and state reporting data to enforce rebates.
- Rebates are calculated quarterly based on price increases exceeding inflation (using the Consumer Price Index for All Urban Consumers).
Significant Changes to Existing Law
- Expansion of Rebate Scope: Current law (from the Inflation Reduction Act of 2022) limits rebates to drugs used in Medicare Parts B and D. This bill broadens it to include commercial market sales, increasing the total units subject to rebates and potentially raising manufacturer obligations.
- Base Year Adjustment: Moves the reference point for price comparisons five years earlier (from 2021 to 2016), which could result in higher rebates if drug prices have risen more significantly since 2016 compared to the 2021 baseline.
- Data and Exclusion Refinements: Introduces specific exclusions (e.g., Medicaid and 340B units) and standardizes unit measurements to "billing units" for consistency, replacing vague terms like "units" in prior law.
Potential Impacts
- On Citizens: Could lower out-of-pocket drug costs for individuals with commercial insurance by pressuring manufacturers to cap price increases or absorb rebates, indirectly benefiting families through stabilized premiums and copays.
- On Government Agencies: CMS will handle expanded data collection and rebate enforcement, potentially increasing administrative workload but reducing Medicare spending through higher rebates (estimated savings could flow back to the program or beneficiaries).
- On International Relations: Minimal direct impact, though it may influence global drug pricing negotiations by signaling U.S. commitment to curbing pharmaceutical profits.
- Broader Economy: Manufacturers might face higher costs, possibly leading to innovation trade-offs or supply chain adjustments, while insurers and employers could see reduced drug spending in commercial plans.
Main Stakeholders Affected
- Drug Manufacturers: Primary payers of rebates; face increased financial liability from broader application and earlier base year, potentially affecting profitability.
- Medicare Beneficiaries: Gain from stabilized or lower drug prices in Parts B and D, with rebates helping fund program benefits.
- Commercial Insurers and Patients: Benefit indirectly as rebates apply to non-Medicare markets, possibly leading to lower premiums or copays for employer-sponsored and individual plans.
- Safety-Net Providers (e.g., Hospitals in 340B Program): Protected by unit exclusions, avoiding rebate impacts on discounted drugs.
- Federal Government (CMS and Treasury): Oversees implementation; rebates could generate revenue for Medicare trust funds.
- States and Medicaid Programs: Unaffected directly, as their units are excluded from calculations.
Notable Legal, Constitutional, or Political Implications
- Legal: Builds on the Inflation Reduction Act without altering core rebate mechanics, but expands them constitutionally under Congress's spending power (Article I, Section 8) to regulate interstate commerce in pharmaceuticals. May invite challenges from manufacturers on data reporting burdens or retroactive-like base year changes, though effective dates mitigate this.
- Constitutional: No apparent conflicts; reinforces federal authority over health programs without infringing state rights, as Medicaid exclusions preserve federal-state balance.
- Political: Supports bipartisan goals of drug affordability (introduced by a mix of Democrats), but could spark debate over pharma industry impacts—potentially increasing legislative scrutiny in the Finance Committee. If passed, it advances Democratic priorities on healthcare costs amid ongoing negotiations over drug pricing reforms.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Cortez Masto, Catherine [D-NV]
Cosponsors (13)
Sen. Klobuchar, Amy [D-MN], Sen. Wyden, Ron [D-OR], Sen. Baldwin, Tammy [D-WI], Sen. Reed, Jack [D-RI], Sen. Smith, Tina [D-MN], Sen. Blumenthal, Richard [D-CT], Sen. King, Angus S., Jr. [I-ME], Sen. Welch, Peter [D-VT], Sen. Hickenlooper, John W. [D-CO], Sen. Slotkin, Elissa [D-MI], Sen. Gallego, Ruben [D-AZ], Sen. Luján, Ben Ray [D-NM], Sen. Merkley, Jeff [D-OR]
Recent Actions
- 2025-03-27: Read twice and referred to the Committee on Finance.
- 2025-03-27: Introduced in Senate
Bill Versions
- Lower Drug Costs for Families Act — issued 2025-03-27 — PDF (8 pages)